Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Opgen Inc
(NQ:
OPGN
)
2.300
+0.020 (+0.88%)
Streaming Delayed Price
Updated: 3:13 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Opgen Inc
< Previous
1
2
Next >
OpGen Receives Nasdaq Notice Regarding Delayed Form 10-K
April 23, 2024
From
OpGen, Inc.
Via
GlobeNewswire
OpGen Announces Acquisition of Preferred Stock by David Lazar
March 25, 2024
From
OpGen, Inc.
Via
GlobeNewswire
OpGen Reports Third Quarter 2023 Financial Results and Provides Business Update
November 14, 2023
From
OpGen, Inc.
Via
GlobeNewswire
OpGen Enters Into Warrant Inducement Transaction for up to $11.2 Million in Gross Proceeds
October 12, 2023
From
OpGen, Inc.
Via
GlobeNewswire
Navigating the Roller Coaster of Recent Penny Stock Surges
October 08, 2023
Recent surges in penny stocks, like Secoo (SECO), Tempest Therapeutics (TPST), and OpGen (OPGN), have fueled speculation and excitement in penny stocks.
Via
MarketBeat
OpGen Reports Second Quarter 2023 Financial Results and Provides Business Update
August 10, 2023
From
OpGen, Inc.
Via
GlobeNewswire
OpGen’s Subsidiary Ares Genetics Releases New Features to its AREScloud Offering
August 07, 2023
From
OpGen, Inc.
Via
GlobeNewswire
OpGen’s Subsidiary Curetis and FIND Extend R&D Collaboration Agreement
August 03, 2023
From
OpGen, Inc.
Via
GlobeNewswire
OpGen to Provide Business Update and Financial Results for the Second Quarter 2023 on August 10th at 4:30 p.m. Eastern Time
August 03, 2023
From
OpGen, Inc.
Via
GlobeNewswire
OpGen’s Subsidiary Curetis Meets Milestones of Extended and Expanded R&D Collaboration with FIND
July 19, 2023
From
OpGen, Inc.
Via
GlobeNewswire
OpGen Subsidiary Ares Genetics Successfully Maintains Key Patent under Opposition in Europe
June 26, 2023
From
OpGen, Inc.
Via
GlobeNewswire
OpGen’s Subsidiary Curetis Receives Batch of Ten New C-Series Unyvero A30 Instruments
June 22, 2023
From
OpGen, Inc.
Via
GlobeNewswire
OpGen Presents Unyvero Urinary Tract Infection Panel Trial Results at ASM Microbe 2023 Conference
June 20, 2023
From
OpGen, Inc.
Via
GlobeNewswire
OpGen Reports First Quarter 2023 Financial Results and Provides Business Update
May 15, 2023
From
OpGen, Inc.
Via
GlobeNewswire
OpGen to Provide Business Update and Financial Results for the First Quarter 2023 on May 15th at 4:30 p.m. Eastern Time
May 08, 2023
From
OpGen, Inc.
Via
GlobeNewswire
OpGen Announces Closing of $3.5 Million Public Offering
May 04, 2023
From
OpGen, Inc.
Via
GlobeNewswire
OpGen Announces Pricing of $3.5 Million Public Offering
May 01, 2023
From
OpGen, Inc.
Via
GlobeNewswire
OpGen’s Subsidiary Curetis Meets All Remaining Key Milestones in R&D Collaboration with FIND
April 26, 2023
From
OpGen, Inc.
Via
GlobeNewswire
OpGen Enters Into Distribution Agreement for Unyvero in the U.S. with Fisher Healthcare
April 18, 2023
From
OpGen, Inc.
Via
GlobeNewswire
OpGen Submits De Novo request to the U.S. FDA for Unyvero Urinary Tract Infection Panel
April 18, 2023
From
OpGen, Inc.
Via
GlobeNewswire
OpGen’s Subsidiary Curetis Signs Expansion of R&D Collaboration with FIND
April 05, 2023
From
OpGen, Inc.
Via
GlobeNewswire
OpGen’s Subsidiary Curetis Meets Milestones in Collaborative Research Project with InfectoGnostics
April 03, 2023
From
OpGen, Inc.
Via
GlobeNewswire
CORRECTION – OpGen Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 30, 2023
From
OpGen, Inc.
Via
GlobeNewswire
OpGen Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 29, 2023
From
OpGen, Inc.
Via
GlobeNewswire
OpGen to Provide Business Update and Financial Results for the Fourth Quarter and Full Year 2022 on March 29th at 4:30 p.m. Eastern Time
March 22, 2023
From
OpGen, Inc.
Via
GlobeNewswire
OpGen Subsidiary Ares Genetics Announces its Move to New Vienna Location and Provides Update on Business Growth
March 01, 2023
From
OpGen, Inc.
Via
GlobeNewswire
OpGen Announces Exercise of All Prefunded Warrants
February 17, 2023
From
OpGen, Inc.
Via
GlobeNewswire
OpGen subsidiary Ares Genetics announces granting of key patent in China
January 26, 2023
From
OpGen, Inc.
Via
GlobeNewswire
OpGen Provides Preliminary Unaudited Revenue for FY 2022 and Business Update
January 18, 2023
From
OpGen, Inc.
Via
GlobeNewswire
OpGen Subsidiary Curetis Meets Several Key Milestones in FIND Collaboration Project
January 17, 2023
Successful delivery of milestones triggers milestone payment
From
OpGen, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.